ArticleBMC cancer2026
Beyond TNM staging: validation of a CT-derived nutritional-inflammatory composite model (RFMmSIS) for prognostication in resectable gastric cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundPrognostic models for resectable gastric cancer rarely integrate adipose tissue and immune-inflammatory parameters. This study evaluated the predictive value of preoperative relative fat mass (RFM) and the modified systemic inflammation score (mSIS), and explored their potential synergy with nanomedicine-based theranostics.
methodsWe retrospectively analyzed 518 patients who underwent radical gastrectomy across three tertiary centers in China (overall enrollment period: 2010-2019). Preoperative CT-derived waist circumference at L3 was used to calculate RFM, with the optimal cutoff determined by ROC analysis using the Youden index. Univariate and multivariate Cox regressions identified independent prognostic factors and constructed the nutritional-inflammatory composite parameter RFMmSIS. Predictive performance was assessed using AUC, AIC, BIC, NRI, IDI, and DCA. Postoperative follow-up was conducted every 3 months during the first 2 years, every 6 months during years 3 through 5, and annually thereafter.
resultsPatients were randomly allocated to training (n = 362) and validation (n = 156) cohorts. RFM outperformed BMI for survival prediction (AUC: 0.584 vs. 0.503, P < 0.05) and was associated with worse 3-year overall survival (OS) (64.1% vs. 80.0%, P = 0.014) and disease-free survival (DFS) (57.7% vs. 78.4%, P = 0.005). Multivariate analysis identified RFM (HR: 2.355) and mSIS grade 2 (HR: 1.657) as independent prognostic factors. The composite RFMmSIS stratified patients into high-, intermediate-, and low-risk groups, with higher scores associated with increased severe complications (Clavien-Dindo ≥IIIa: 4.7% vs. 4.2% vs. 15.2%, P = 0.005 in training cohort) and poorer 3-year OS/DFS (high-risk: 44.3%/41.0%). RFMmSIS demonstrated superior predictive accuracy for OS and DFS compared with operative extent and pN stage (all P < 0.05).
conclusionsPreoperative RFMmSIS is a clinically feasible predictor of short-term complications and long-term survival in gastric cancer, offering enhanced prognostic stratification beyond traditional parameters and providing a rationale for integrating nutritional-inflammatory risk assessment with nanomedicine-based theranostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.